Kieser Brian Joseph's Form 4 filing
Nexgel, Inc.NXGL · filed Nov 13, 2026
- Accession no.
- 0001493152-26-051920
- Filed
- Nov 13, 2026, 9:59 PM ET
- Trade date
- Nov 10, 2026
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 9 derivative transactions. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kieser Brian JosephCIK 0002133654 | Director, Officer (Interim CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Common Stock | PPurchaseAcquired | +133,216 | $5.50F1 | +$732,688 | 133,216 | Indirect | Price outlier |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Common Stock | PPurchaseAcquired | +133,216 | $0.00F1 | $0 | 133,216 | Indirect | |
| Nov 10, 2026 | Common Stock | DReturned to the companyAcquired | +83,334 | –F3 | – | 0 | Direct | |
| Nov 10, 2026 | Common Stock | AGrant or awardAcquired | +181,819 | –F3 | – | 181,819 | Direct | |
| Nov 10, 2026 | Common Stock | DReturned to the companyAcquired | +41,667 | –F3 | – | 0 | Direct | |
| Nov 10, 2026 | Common Stock | AGrant or awardAcquired | +41,667 | –F3 | – | 41,667 | Direct | |
| Nov 10, 2026 | Common Stock | DReturned to the companyAcquired | +458,334 | –F3 | – | 0 | Indirect | |
| Nov 10, 2026 | Common Stock | AGrant or awardAcquired | +1,000,000 | –F3 | – | 1,000,000 | Indirect | |
| Nov 10, 2026 | Common Stock | DReturned to the companyAcquired | +229,167 | –F3 | – | 0 | Indirect | |
| Nov 10, 2026 | Common Stock | AGrant or awardAcquired | +229,167 | –F3 | – | 229,167 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Reflects the purchase by Sequence LifeScience, Inc. ("Sequence") on November 10, 2026 of 133,216 units from the Issuer, each unit consisting of one share of Common Stock and a warrant to purchase one share of Common Stock (the "PIPE Warrant"), at $5.50 per unit, in a private placement under a Securities Purchase Agreement. No separate consideration was paid for the PIPE Warrant. The closing occurred on November 10, 2026. The PIPE Warrant has an original issue date of November 10, 2026, is exercisable for cash at $10.00 per share, and expires on the fifth anniversary of its original issue date. The Issuer has waived the beneficial-ownership limitation that would otherwise apply to these securities.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.
- F3
On November 10, 2026, the Reporting Person and Sequence entered into Note Amendment and Conversion Agreements with the Issuer that, among other things, reduced the conversion price of each Convertible Promissory Note from $12.00 to $5.50 per share and the exercise price of each Existing Warrant from $16.00 to $13.00 per share. The amendments are reported as the disposition of the original derivative security and the acquisition of the amended derivative security. The original securities are treated as disposed of solely for purposes of this Form 4 reporting; they were amended and remain outstanding as amended. The transactions were approved in advance by the Issuer's Board of Directors on November 10, 2026 for purposes of Rule 16b-3(d) and (e). Share amounts reflect the 1-for-20 reverse stock split effective October 12, 2026. The Note and Existing Warrant held directly were issued on May 11, 2026, and those held by Sequence were issued on April 17, 2026.
Referenced by the price of 8 transactions in Table II.